Showing 15 posts of 21 posts found.

Senate puts forward bipartisan bill to lower price of drugs

July 24, 2019
Research and Development PBMs, Senate, USA, access, bipartisan, pharma, pricing

The Senate Finance Committee has introduced a bipartisan bill that aimed at lowering the prices Medicare pays for pharmaceutical drugs. …


Prices hiked on 3,400 drugs in first half of 2019

July 4, 2019
Research and Development, Sales and Marketing abstruse, access, generics, pharma, prescription, pricing

There have been price hikes on more than 3,400 drugs in the United States in the first six months of …


MPs discuss breaking Vertex’s IP rights to bring Orkambi to UK

June 11, 2019
Research and Development Orkambi, Vertex, access, house of commons, pharma, pricing

MPs yesterday discussed circumventing Vertex’s patent on cystic fibrosis medicine Orkambi (Lumacaftor/ivacaftor) as a means of breaking the deadlock and …


UK government refuses to sign up to WHO pricing transparency resolution

May 29, 2019
Research and Development WHA, WHO, access, health UK, pharma, pricing

The UK government has refused to sign up to a global resolution on transparency in drug pricing which urges governments …


Novartis’ $2.15m SMA drug Zolgensma becomes most expensive FDA-approved therapy

May 28, 2019
Manufacturing and Production AveXis, FDA, Zolgensma, access, drugs, pricing, sma

The FDA has approved Novartis subsidiary AveXis’ $2.15 million gene therapy Zolgensma for children with spinal muscular atrophy (SMA). The …

The price of access: Can the NHS afford Orkambi?

April 29, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug pricing, NHS, NICE, Orkambi, UK, Vertex, access, cystic fibrosis, feature, pharma, pricing

The impasse over access to Vertex’s Orkambi for cystic fibrosis patients in England and Wales has revealed the cracks in …

ICR calls for faster access to innovative cancer drugs

April 25, 2019
Medical Communications, Research and Development, Sales and Marketing Cancer, ICR, R&D, access, cancer drugs, incentives, innovation, oncology, pricing

The Institute of Cancer Research (ICR) has called for faster access to innovative cancer drugs in the UK. The call …


Médecins Sans Frontières (MSF)/ Doctors Without Borders calls on CEPI to revise ‘toothless’ access policy

March 6, 2019
Sales and Marketing CEPI, MSF, access, public health, tokyo, vaccines

The humanitarian organisation Médecins Sans Frontières (MSF) has called on The Coalition for Epidemic Preparedness Innovations (CEPI) to revise their …

Pharmacists warn of shortages in England

January 18, 2019
Medical Communications access, pharmacists, pricing, shortages

Pharmacists in England have warned that they are struggling to obtain many common generic medicines, as the number of medicines …


Sanders calls on Trump to support drug pricing bill

January 11, 2019
Medical Communications Bernie Sanders, Trump, access, pharma, pricing

Senator Bernie Sanders has called on President Donald Trump to support new legislation aimed at cutting prices on prescription drugs. …


NICE give go-ahead to Gilead’s Yescarta for adults with lymphoma

December 7, 2018
Medical Communications Cancer, Cost, Gilead, NHS, NICE, Yescarta, access

The NHS cost effectiveness body NICE has approved Gilead’s Yescarta for treatment of come adults with lymphoma. Gilead’s treatment will …


GSK retain top spot on access to medicines list

November 22, 2018
Business Services, Research and Development GSK, J&J, JJ, R&D, Sanofi, access, low and middle income countries, researh

The majority (63%) of research and development projects are being conducted by just five companies; GSK, Johnson & Johnson, Sanofi, …


Trump administration propose ruling requiring price transparency on TV ads

October 16, 2018
Manufacturing and Production Alex Azar, Drug pricing, Trump, access, adverts

US Health and Human Services Secretary Alex Azar, has announced a proposal which would require pharma firms to include the …


NICE decision could limit future development of CAR T therapies; Evelyn Warner comments on NICE’s decision making process

September 25, 2018
Research and Development CAR T, CAR-T, Cancer, Duff and Phelps, Kymriah, access, oncology, pricing

Lack of access to CAR T therapies in the United Kingdom could hinder the development of effective personalised cancer treatments, …


J&J pledges to end global TB pandemic

September 25, 2018
Manufacturing and Production J&J, JJ, Johnson and Johnson, TB, access, tuberculosis

Johnson and Johnson have announced that they are launching a 10-year initiative aimed at helping to end tuberculosis, the world’s …

Latest content